MK-677Evidence & Dosage

Top studies on MK-677

Ranked by influential-citation count and publication year.

1. 01

   Design and biological activities of L-163,191 (MK-0677): a potent, orally active growth hormone secretagogue.

   Proceedings of the National Academy of Sciences of the United States of America·199579 influential citations

   A potent, orally active growth hormone (GH) secretagogue L-163,191 belonging to a recently synthesized structural class has been characterized. L-163,191 releases GH from rat pituitary cells in culture with EC50 = 1.3 +/- 0.09 nM and is…

2. 02

   Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretogogue (MK-677) in healthy elderly subjects.

   The Journal of clinical endocrinology and metabolism·1996·n=1776 influential citations

   Aging is associated with declining activity of the GH axis, possibly contributing to adverse body composition changes and increased incidence of cardiovascular disease. The stimulatory effects on the GH-insulin-like growth factor I (IGF-I)…

3. 03

   Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial.

   Annals of internal medicine·2008·n=5357 influential citations

   <h4>Background</h4>Growth hormone secretion and muscle mass decline from midpuberty throughout life, culminating in sarcopenia, frailty, decreased function, and loss of independence. The decline of growth hormone in the development of…

4. 04

   The effects of treatment and the individual responsiveness to growth hormone (GH) replacement therapy in 665 GH-deficient adults. KIMS Study Group and the KIMS International Board.

   The Journal of clinical endocrinology and metabolism·1999·n=66543 influential citations

   Data from 665 adults with GH deficiency (GHD; 332 women; 169 childhood-onset GHD; mean age, 44 yr) were analyzed to determine the efficacy of and individual responsiveness to GH replacement therapy. GH replacement was started at enrolment…

5. 05

   Effects of progestin-opposed transdermal estrogen administration on growth hormone and insulin-like growth factor-I in postmenopausal women of different ages.

   The Journal of clinical endocrinology and metabolism·199143 influential citations

   Prior studies in women have shown a positive correlation of endogenous estrogen levels with spontaneous and stimulated GH secretion and basal insulin-like growth factor-I (IGF-I) levels. In postmenopausal women, estrogen replacement…

6. 06

   Effects of a novel glucagon receptor antagonist (Bay 27-9955) on glucagon-stimulated glucose production in humans.

   Diabetologia·2001·n=838 influential citations

   <h4>Aims/hypothesis</h4>To study the effects of a specific glucagon receptor antagonist (Bay 27-9955), on plasma glucose concentrations and rates of glucose production in response to hyperglucagonaemia in humans.<h4>Methods</h4>The study…

7. 07

   Effects of an oral growth hormone secretagogue in older adults.

   The Journal of clinical endocrinology and metabolism·2009·n=39536 influential citations

   <h4>Context</h4>GH secretion declines with age, possibly contributing to reduced muscle mass, strength, and function. GH secretagogues (GHS) may increase muscle mass and physical performance.<h4>Objectives/design</h4>We conducted a…

8. 08

   Growth hormone in the aging male.

   Best practice &amp; research. Clinical endocrinology &amp; metabolism·2013·n=2,69425 influential citations

   Secretion of growth hormone (GH) and IGF-1 levels decline during advancing years-of-life. These changes (somatopause) are associated with loss of vitality, muscle mass, physical function, together with the occurrence of frailty, central…

9. 09

   Inhibition of growth of human osteosarcomas by antagonists of growth hormone-releasing hormone.

   Journal of the National Cancer Institute·199524 influential citations

   <h4>Background</h4>Insulin-like growth factor I (IGF-I) may be involved in the proliferation of human osteosarcomas. Most of the IGF-I found in blood is produced in the liver, where transcription of the IGF-I gene is regulated by growth…

10. 10

    Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial.

    Neurology·2008·n=56320 influential citations

    <h4>Background</h4>In animals, insulin-like growth factor-1 (IGF-1) increases clearance of beta-amyloid, a pathologic hallmark of Alzheimer disease (AD), from the CNS. Serum IGF-1 level decreases with age, and shows a further decrease in…